Platelet Function and Hemostasis

1. Quick Answer (30-Second Summary)

Platelets are anucleate cell fragments derived from megakaryocytes that play a central role in primary hemostasis through adhesion, activation, and aggregation at sites of vascular injury.

Key Concepts:

• Adhesion: GPIb-IX-V binds von Willebrand factor (vWF) on exposed collagen
• Activation: Thromboxane A2, ADP, and thrombin trigger platelet shape change and granule release
• Aggregation: GPIIb/IIIa (integrin αIIbβ3) binds fibrinogen to cross-link platelets
• Coagulation Integration: Activated platelets provide phosphatidylserine surface for thrombin generation

ICU Relevance:

• Thrombocytopenia is common (affecting 20-40% of ICU patients)
• Point-of-care testing (TEG/ROTEM/Multiplate) guides transfusion
• HIT is a prothrombotic emergency despite low platelet count
• Antiplatelet agents require specific reversal strategies

Exam Focus:

• Structure and function of platelet glycoproteins (GPIb, GPIIb/IIIa)
• Mechanisms of antiplatelet agents
• Transfusion thresholds and indications
• HIT pathophysiology and 4Ts score

---

2. CICM First Part Exam Focus

What Examiners Expect

Written SAQ:

Common question stems:

• "Describe the structure of a platelet and its role in primary hemostasis" (10 marks)
• "Outline the mechanisms of action of antiplatelet agents" (10 marks)
• "Explain the pathophysiology of heparin-induced thrombocytopenia" (10 marks)
• "Compare and contrast TEG and ROTEM in assessing platelet function" (10 marks)
• "Draw and label a diagram showing platelet adhesion and aggregation" (5 marks)

Expected depth:

• Detailed molecular mechanisms at receptor/signaling level
• Quantitative values (normal platelet count, half-lives, transfusion thresholds)
• Clear diagrams with properly labeled glycoproteins
• Clinical ICU relevance explicitly stated
• Integration with coagulation cascade

Written MCQ:

Common topics tested:

• Glycoprotein receptor functions (GPIb vs GPIIb/IIIa)
• Granule contents (alpha vs dense)
• Antiplatelet agent mechanisms and pharmacokinetics
• Platelet transfusion thresholds
• TEG/ROTEM parameter interpretation
• HIT 4Ts scoring

Oral Viva:

Expected discussion flow:

1. Define/Describe - Platelet structure and origin
2. Explain Mechanism - Adhesion, activation, aggregation pathways
3. Quantify - Normal values, half-lives, transfusion thresholds
4. Apply to ICU - Bleeding patient management, HIT recognition
5. Compare/Contrast - Antiplatelet agents, viscoelastic testing
6. Integrate - Cell-based coagulation model

Common viva scenarios:

• Massive transfusion with ongoing bleeding - what tests, what products?
• Post-cardiac surgery patient with thrombocytopenia - differential diagnosis
• Trauma patient on aspirin - management approach
• Suspected HIT - investigation and management

Pass vs Fail Performance

Pass Standard:

• Accurate platelet structure knowledge (granules, glycoproteins)
• Clear explanation of adhesion-activation-aggregation sequence
• Correct antiplatelet agent mechanisms
• Ability to apply to ICU clinical scenarios
• Draws clear diagram of platelet plug formation

Common Reasons for Failure:

• Confusing GPIb (adhesion) with GPIIb/IIIa (aggregation)
• Not knowing granule contents (alpha vs dense)
• Incorrect transfusion thresholds
• Poor understanding of HIT paradox (thrombosis despite thrombocytopenia)
• Cannot explain cell-based coagulation model

---

3. Key Points

Must-Know Facts

1. Platelet Production: Megakaryocytes in bone marrow produce 100-150 x 10^9 platelets/day; regulated by thrombopoietin (TPO) from liver. Normal count: 150-400 x 10^9/L; lifespan 8-10 days. PMID: 16553548

2. GPIb-IX-V Complex: Primary adhesion receptor binding vWF on exposed subendothelial collagen. Deficiency causes Bernard-Soulier syndrome (giant platelets, bleeding). PMID: 10694961

3. GPIIb/IIIa (Integrin αIIbβ3): Final common pathway for aggregation; binds fibrinogen and vWF. Present at ~80,000 copies per platelet. Deficiency causes Glanzmann thrombasthenia. PMID: 16452920

4. Alpha Granules: Contain fibrinogen, vWF, Factor V, platelet-derived growth factor (PDGF), P-selectin. Released during activation. Grey platelet syndrome = alpha granule deficiency. PMID: 24249617

5. Dense (Delta) Granules: Contain ADP, ATP, serotonin, calcium, pyrophosphate. ADP amplifies platelet recruitment. Storage pool disease = dense granule deficiency. PMID: 12414652

6. Thromboxane A2 (TXA2): Synthesized from arachidonic acid via COX-1; potent vasoconstrictor and platelet activator. Target of aspirin. Half-life ~30 seconds. PMID: 6113765

7. HIT (Heparin-Induced Thrombocytopenia): Antibodies to PF4-heparin complexes cause FcγRIIa-mediated platelet activation. Prothrombotic despite low count. 4Ts score for diagnosis. PMID: 25904065

Essential Equations

Platelet Recovery:

Corrected Count Increment (CCI) = (Post-Tx count - Pre-Tx count) x BSA / Platelets transfused (x10^11)

• Expected CCI: 10-20 x 10^9/L at 1 hour
• CCI <7.5 at 1 hour = refractoriness

Bleeding Time (Historical):

Bleeding time = f(platelet count, platelet function, vWF, vessel wall)

• Normal: 2-9 minutes (Ivy method)
• Not reliable for predicting surgical bleeding

Normal Values Table

---

4. Detailed Content

4.1 Platelet Structure

Ultrastructure

Plasma Membrane:

• Open canalicular system (OCS): Invaginations of plasma membrane that increase surface area for granule release and receptor expression. PMID: 15769624
• Dense tubular system (DTS): Smooth ER remnant storing calcium; regulates intracellular calcium for activation
• Glycocalyx: Rich in glycoproteins (receptors for adhesion/aggregation)

Surface Glycoproteins:

Reference: PMID: 21800455 (Versteeg - comprehensive review of platelet receptors)

Granule Contents

Alpha Granules (50-80 per platelet):

Dense Granules (3-8 per platelet):

Lysosomes: Acid hydrolases for clot remodeling

Reference: PMID: 24249617 (Blair - platelet granule biogenesis)

4.2 Primary Hemostasis: Adhesion, Activation, Aggregation

Phase 1: Adhesion

Mechanism:

1. Vascular injury exposes subendothelial collagen (types I, III, VI)
2. von Willebrand factor (vWF) in plasma binds to exposed collagen via its A3 domain
3. Under high shear stress (arteries, arterioles), vWF uncoils exposing A1 domain
4. GPIb-IX-V complex on platelets binds vWF A1 domain
5. This "tethering" allows rolling adhesion, slowing platelets for firmer attachment
6. GPVI and GPIa/IIa then bind directly to collagen for stable adhesion

Shear Rate Dependence:

• Low shear (<1000 s⁻¹): Direct collagen-GPVI/GPIa-IIa binding sufficient
• High shear (>1000 s⁻¹): GPIb-vWF interaction essential (arterial circulation)

Clinical Relevance:

• Bernard-Soulier syndrome: GPIb-IX-V deficiency → impaired adhesion, giant platelets, bleeding
• von Willebrand disease: vWF deficiency/dysfunction → mucocutaneous bleeding
• Type 2B vWD: Gain-of-function vWF with enhanced GPIb binding → thrombocytopenia

Reference: PMID: 10694961 (Andrews - GPIb-IX-V complex review)

Phase 2: Activation

Signaling Pathways:

1. Collagen Pathway (GPVI):

• GPVI binds collagen → Src family kinase activation → PLCγ2 activation
• IP3 → calcium release from DTS
• DAG → protein kinase C activation
• Result: Shape change, granule release, integrin activation

2. Thrombin Pathway (PAR-1, PAR-4):

• Thrombin cleaves N-terminus of PAR-1 (primary) and PAR-4
• Creates tethered ligand that auto-activates receptor
• G-protein coupled signaling → PLC activation → calcium/DAG
• Most potent platelet activator

3. Thromboxane A2 Pathway:

• Arachidonic acid released from membrane by PLA2
• COX-1 converts to PGH2 → thromboxane synthase → TXA2
• TXA2 binds TPα receptor (autocrine and paracrine)
• Amplifies activation; target of aspirin

4. ADP Pathway:

• ADP released from dense granules
• P2Y1: Gq-coupled → calcium mobilization, shape change
• P2Y12: Gi-coupled → inhibits adenylyl cyclase → reduces cAMP
• P2Y12 is target of clopidogrel, prasugrel, ticagrelor, cangrelor

Shape Change:

• Calcium influx activates myosin light chain kinase
• Actin-myosin contraction
• Disc → sphere with pseudopodia (increased surface area)
• Facilitates granule centralization and release

Granule Release (Secretion):

• SNARE protein-mediated fusion with OCS/plasma membrane
• Alpha granules: fibrinogen, vWF, Factor V, P-selectin
• Dense granules: ADP, ATP, serotonin, calcium

Phosphatidylserine Exposure:

• Scramblase activation flips PS to outer membrane leaflet
• Creates negatively charged surface for coagulation factor assembly
• Essential for tenase and prothrombinase complex formation

Reference: PMID: 24335720 (Li - platelet signaling review)

Phase 3: Aggregation

GPIIb/IIIa Activation:

• Inside-out signaling from activation pathways
• Conformational change in GPIIb/IIIa → high affinity state
• Exposes RGD-binding site for fibrinogen

Fibrinogen Cross-Linking:

• Fibrinogen is bivalent (two RGD motifs)
• Binds GPIIb/IIIa on two adjacent platelets
• Creates platelet-fibrinogen-platelet bridges
• Forms primary hemostatic plug

Outside-In Signaling:

• Fibrinogen binding triggers outside-in signals
• Src family kinases, focal adhesion kinase
• Cytoskeletal reorganization, clot retraction
• Irreversible platelet aggregation

Clot Stabilization:

• Factor XIIIa (activated by thrombin) cross-links fibrin
• Platelet contraction (thrombosthenin) compacts clot
• Clot retraction occurs over 1-2 hours

Reference: PMID: 16452920 (Bennett - GPIIb/IIIa structure and function)

4.3 Coagulation Cascade Integration: Cell-Based Model

The cell-based model of hemostasis emphasizes that coagulation occurs on specific cell surfaces in overlapping phases. PMID: 11709211 (Hoffman & Monroe)

Phase 1: Initiation (TF-Bearing Cells)

1. Vascular injury exposes tissue factor (TF) on subendothelial cells
2. TF binds circulating Factor VIIa → TF-VIIa complex
3. TF-VIIa activates small amounts of Factor IX and Factor X
4. Factor Xa + Va generates small amount of thrombin ("priming dose")
5. This thrombin is insufficient for stable clot but critical for amplification

Note: TFPI rapidly inhibits TF-VIIa-Xa, limiting initiation phase

Phase 2: Amplification (Platelet Surface)

1. "Priming dose" thrombin activates platelets via PAR-1/PAR-4
2. Thrombin activates Factor V → Va on platelet surface
3. Thrombin activates Factor VIII → VIIIa (released from vWF)
4. Thrombin activates Factor XI → XIa
5. Activated platelets expose phosphatidylserine (PS)
6. PS provides negatively charged surface for factor assembly

Phase 3: Propagation (Platelet Surface)

1. Tenase complex forms on PS: IXa + VIIIa + Ca²⁺
2. Tenase activates Factor X → Xa (50-100× more efficient than TF-VIIa)
3. Prothrombinase complex forms: Xa + Va + Ca²⁺
4. Prothrombinase generates thrombin burst
5. Massive thrombin converts fibrinogen → fibrin
6. Thrombin activates Factor XIII → fibrin cross-linking

Platelet Contribution to Coagulation

Reference: PMID: 11709211 (Hoffman - cell-based model of hemostasis)

4.4 Platelet Activation Pathways: Detailed Pharmacology

Thromboxane A2 Pathway

Synthesis:

Membrane phospholipid → Arachidonic acid (PLA2)
                        ↓
                   COX-1 enzyme
                        ↓
                      PGH2
                        ↓
               Thromboxane synthase
                        ↓
                      TXA2

Pharmacology:

• COX-1 is constitutively expressed in platelets
• COX-2 is inducible but not significant in mature platelets
• TXA2 half-life: ~30 seconds (rapidly hydrolyzed to inactive TXB2)
• TPα receptor: Gq-coupled → IP3/DAG pathway

Aspirin Mechanism:

• Irreversibly acetylates Ser529 of COX-1 active site
• Prevents arachidonic acid access
• Effect lasts lifetime of platelet (8-10 days)
• Low-dose (75-100 mg) sufficient for near-complete inhibition

Reference: PMID: 6113765 (FitzGerald - thromboxane and vascular disease)

ADP Pathway

Receptors:

P2Y12 Importance:

• Essential for sustained aggregation
• Amplifies responses to other agonists
• Target of thienopyridines and ticagrelor
• Genetic deficiency causes mild-moderate bleeding

Reference: PMID: 11157473 (Hollopeter - P2Y12 identification)

Thrombin Pathway

Receptors:

• PAR-1: Primary thrombin receptor in humans; high affinity (EC50 ~0.1 nM)
• PAR-4: Secondary receptor; lower affinity (EC50 ~5 nM)

Signaling:

• Thrombin cleaves N-terminus → tethered ligand auto-activation
• G12/13 → Rho kinase → shape change
• Gq → PLCβ → IP3/DAG/calcium
• Most potent platelet agonist

Clinical Relevance:

• Vorapaxar is a PAR-1 antagonist (FDA approved)
• Reduces cardiovascular events but increases bleeding

Reference: PMID: 10805779 (Coughlin - thrombin signaling in platelets)

4.5 Antiplatelet Agents

Classification and Mechanisms

Aspirin

Pharmacology:

• Oral bioavailability: ~50% (due to hepatic first-pass)
• Onset: 15-30 minutes (chewable faster)
• Plasma half-life: 15-20 minutes (but effect lasts platelet lifespan)
• Dose: 75-100 mg daily for antiplatelet effect

ICU Considerations:

• Enteric-coated may have delayed absorption in critically ill
• Consider IV or suppository in NPO patients
• Resistance in 5-40% (CYP2C19, compliance, drug interactions)

Reversal:

• No specific antidote
• Platelet transfusion (one adult dose raises count ~30 x 10^9/L)
• DDAVP may enhance platelet function
• Effect of transfused platelets shortened by circulating aspirin

Reference: PMID: 12490960 (Patrono - aspirin pharmacology)

Clopidogrel

Pharmacology:

• Prodrug requiring hepatic activation
• CYP2C19 is rate-limiting enzyme (genetic polymorphism significant)
• Active metabolite is short-lived (~30 min)
• Binds P2Y12 irreversibly (disulfide bond)
• 300-600 mg loading, 75 mg maintenance
• Steady state: 3-7 days without loading

CYP2C19 Polymorphism (PMID: 19779154):

• *1/*1 (extensive metabolizer): Normal response
• *2 or *3 allele (poor metabolizer): Reduced effect, increased cardiovascular events
• Prevalence: 25-30% Caucasians, 40-50% Asians carry at least one loss-of-function allele

Reversal:

• No specific antidote
• Platelet transfusion (5-7 days for meaningful effect washout)
• Desmopressin may help
• For emergency surgery: Platelet transfusion, accept higher bleeding risk

Reference: PMID: 19779154 (Mega - CYP2C19 and clopidogrel response)

GPIIb/IIIa Inhibitors

Mechanism:

• Block final common pathway of platelet aggregation
• Prevent fibrinogen binding (RGD sequence blocked)
• Most potent antiplatelet agents available

Comparison:

Reversal:

• Stop infusion
• Platelet transfusion (effective for eptifibatide/tirofiban)
• For abciximab: Platelets may be sequestered by antibody

Reference: PMID: 9067181 (Topol - GPIIb/IIIa inhibitors in coronary disease)

4.6 Platelet Disorders

Thrombocytopenia in ICU

Incidence: 20-40% of ICU patients develop thrombocytopenia (PMID: 17062129)

Classification by Mechanism:

ICU-Specific Causes (PMID: 17062129):

• Sepsis (most common cause in ICU)
• Drug-induced (antibiotics, heparin, sedatives)
• DIC
• Massive transfusion
• ECMO/mechanical circulatory support
• Liver disease

Heparin-Induced Thrombocytopenia (HIT)

Pathophysiology (PMID: 25904065):

1. Complex Formation: Platelet factor 4 (PF4) released from activated platelets binds heparin
2. Neoepitope Exposure: PF4-heparin complex undergoes conformational change
3. Antibody Production: IgG against PF4-heparin complex forms (usually days 5-10)
4. Platelet Activation: IgG-PF4-heparin immune complex binds FcγRIIa on platelets
5. Prothrombotic State: Massive platelet activation → microparticle release → thrombin generation

Clinical Features:

• Platelet count typically falls 50% or more
• Nadir usually 50-80 x 10^9/L (rarely <20)
• Thrombosis in 30-50% despite low count (arterial > venous)
• Skin necrosis at injection sites
• Acute systemic reactions (anaphylactoid)

4Ts Score (PMID: 16690238):

Interpretation:

• 0-3: Low probability (<5% chance) - HIT unlikely
• 4-5: Intermediate probability (~10-30%)
• 6-8: High probability (~40-80%)

Laboratory Diagnosis:

• PF4-heparin ELISA: High sensitivity (~98%), lower specificity (~80%)
• Serotonin Release Assay (SRA): Gold standard; high specificity (~98%)
• Heparin-Induced Platelet Aggregation (HIPA): Alternative functional assay

Management (PMID: 30482774 - ASH Guidelines):

1. Stop ALL heparin (including flushes, heparin-coated lines)
2. Start alternative anticoagulant immediately (argatroban, bivalirudin, fondaparinux)
3. Do NOT transfuse platelets (may worsen thrombosis)
4. Screen for thrombosis (Doppler, imaging)
5. Warfarin only after platelet recovery to >150 x 10^9/L

Reference: PMID: 30482774 (Cuker - ASH HIT guidelines 2018)

Qualitative Platelet Disorders

Inherited:

Acquired:

Reference: PMID: 17914153 (Nurden - inherited platelet disorders)

4.7 Platelet Transfusion

Thresholds and Indications

Australian Red Cross Lifeblood / ANZSBT Guidelines (PMID: 25383760):

PACER Trial (PMID: 37224097 - NEJM 2023):

• CVC insertion in thrombocytopenic patients (10-50 x 10^9/L)
• Withholding prophylactic transfusion was NOT non-inferior
• Suggests benefit of platelet transfusion for CVCs if count <50

Platelet Products

Pooled Platelets:

• From 4-6 whole blood donations
• Volume: 250-350 mL
• Dose: ~3 x 10^11 platelets

Apheresis Platelets (Single Donor):

• From single apheresis collection
• Lower alloimmunization risk
• Preferred for HLA-matched/refractory patients

Storage:

• Room temperature (20-24°C) with agitation
• Shelf life: 5-7 days (bacterial contamination risk)
• Cannot be refrigerated (causes GPIb clustering, rapid clearance)

Expected Response:

• 1 adult therapeutic dose increases count by 30-50 x 10^9/L in 70 kg adult
• Refractory if CCI <7.5 at 1 hour post-transfusion

Contraindications and Special Situations

Relative Contraindications:

• TTP (avoid unless life-threatening bleeding)
• HIT (may worsen thrombosis)
• Autoimmune thrombocytopenia (poor response)

Antiplatelet Drug Reversal:

• PATCH trial (PMID: 27342600): Platelet transfusion for ICH on antiplatelets showed HARM
• Reserve for surgical bleeding, not spontaneous ICH

Reference: PMID: 25383760 (Kaufman - AABB platelet transfusion guidelines)

4.8 Point-of-Care Testing

Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM)

Principle: Viscoelastic measurement of clot formation, strength, and lysis

TEG Parameters:

ROTEM Parameters:

Platelet-Specific Assessment:

Reference: PMID: 36852538 (ESAIC 2023 perioperative bleeding guidelines)

Multiplate (Multiple Electrode Aggregometry)

Principle: Measures platelet aggregation by electrical impedance changes

Agonists Used:

Interpretation:

• Results in AUC (Area Under Curve) or Units (U)
• Low AUC = impaired platelet function / drug effect
• ASPI <40 U suggests aspirin effect
• ADP <31 U suggests P2Y12 inhibitor effect

ICU Applications:

• Assessing antiplatelet drug effect pre-procedure
• Guiding platelet transfusion in bleeding
• Monitoring platelet function in ECMO/VAD

Reference: PMID: 25303534 (ISTH platelet function testing)

Comparison of Point-of-Care Tests

Reference: PMID: 28833130 (ESICM consensus on VHAs)

---

5. Graphs and Diagrams

Diagram 1: Platelet Adhesion and Aggregation

Description: Sequential diagram showing:

1. Vascular injury exposing subendothelial collagen
2. vWF binding to collagen and uncoiling under shear
3. GPIb-IX-V complex on platelet binding to vWF A1 domain (ADHESION)
4. GPVI and GPIa/IIa binding directly to collagen
5. Platelet activation - shape change, granule release
6. GPIIb/IIIa conformational change to high-affinity state
7. Fibrinogen cross-linking adjacent platelets (AGGREGATION)

Key Labels:

• Endothelial cells
• Subendothelial collagen (Type I, III)
• vWF (A1 and A3 domains)
• GPIb-IX-V complex
• GPVI receptor
• GPIIb/IIIa (resting vs activated)
• Fibrinogen bridging
• Alpha and dense granule release

Clinical Relevance:

• Explains why GPIb deficiency (Bernard-Soulier) affects adhesion
• Explains why GPIIb/IIIa deficiency (Glanzmann) affects aggregation
• Shows target sites for antiplatelet agents

---

Diagram 2: Platelet Activation Pathways

Description: Flowchart showing three main activation pathways converging on GPIIb/IIIa:

Pathway 1: Thromboxane

Membrane phospholipid → PLA2 → Arachidonic acid
                               ↓
                      COX-1 ← (Aspirin blocks)
                               ↓
                             PGH2
                               ↓
                      Thromboxane synthase
                               ↓
                             TXA2 → TPα receptor

Pathway 2: ADP

Dense granule release → ADP
                         ↓
                P2Y1 (Gq) + P2Y12 (Gi) ← (Clopidogrel blocks P2Y12)
                         ↓
            ↑ Ca²⁺ + ↓ cAMP

Pathway 3: Thrombin

Coagulation cascade → Thrombin
                        ↓
               PAR-1 / PAR-4
                        ↓
               Gq signaling → PLCβ → IP3/DAG

All pathways converge on:

Inside-out signaling → GPIIb/IIIa activation
                              ↓
              Fibrinogen binding ← (GPIIb/IIIa inhibitors block)
                              ↓
                        AGGREGATION

---

Graph 1: Thromboelastography (TEG) Trace

Description: Standard TEG trace showing characteristic "cigar shape":

Key Parameters:

• R time: Beginning to first amplitude of 2 mm (clot initiation)
• K time: From R to amplitude of 20 mm (clot amplification)
• Alpha angle: Slope of tangent from R to K (rate of clot formation)
• MA: Maximum amplitude (maximum clot strength)
• LY30: % reduction in MA at 30 minutes (fibrinolysis)

Abnormal Patterns:

1. Prolonged R: Factor deficiency → give FFP/PCC
2. Decreased MA: Platelet or fibrinogen deficiency → give platelets/fibrinogen
3. Increased LY30: Hyperfibrinolysis → give TXA

---

6. Clinical Application to ICU

ICU Scenario 1: Massive Transfusion

Clinical Situation: Trauma patient with hemorrhagic shock requiring massive transfusion protocol.

Pathophysiology:

• Hemodilution with crystalloid/PRBCs decreases platelets and clotting factors
• Trauma-induced coagulopathy (TIC): Early coagulopathy from tissue injury
• Hypothermia impairs platelet function and enzyme kinetics
• Acidosis impairs coagulation
• Hypocalcemia from citrate in blood products chelates calcium

Management Based on Physiology:

• 1:1:1 Ratio (PROPPR trial, PMID: 25647203): PRBCs:FFP:Platelets
• TEG/ROTEM-guided: More targeted approach reducing overall product use
• Maintain platelets >50 x 10^9/L (>100 in TBI)
• Target fibrinogen >1.5 g/L
• Correct hypothermia (>35°C)
• Correct acidosis (pH >7.2)
• Replace calcium (ionized Ca²⁺ >1.0 mmol/L)

Monitoring:

• POC testing every 30-60 minutes during active hemorrhage
• TEG/ROTEM: R/CT for factors, MA/MCF for platelets/fibrinogen, LY30/ML for fibrinolysis
• Conventional labs: PT, APTT, fibrinogen, platelet count

Reference: PMID: 37046447 (European Trauma Guidelines 2023)

---

ICU Scenario 2: HIT Recognition and Management

Clinical Situation: Post-operative cardiac surgery patient day 7 with platelet count drop from 180 to 75 x 10^9/L.

Clinical Reasoning:

1. Calculate 4Ts score:

   • Thrombocytopenia: Fall >50%, nadir >20 = 2 points
   • Timing: Day 5-10 of heparin = 2 points
   • Thrombosis: Check for DVT/PE, review lines
   • Other causes: Post-CPB consumption, infection, drugs

2. If 4Ts ≥4 (intermediate/high probability):

   • Stop ALL heparin immediately
   • Start alternative anticoagulant (argatroban first-line)
   • Send PF4-heparin ELISA ± SRA
   • Screen for thrombosis

Argatroban Dosing in ICU:

• Standard: 2 mcg/kg/min
• Hepatic impairment: 0.5 mcg/kg/min
• Target APTT ratio: 1.5-3.0
• Monitor anti-Xa if available

Do NOT:

• Transfuse platelets (may worsen thrombosis)
• Start warfarin until platelets >150 (risk of limb gangrene)
• Use LMWH (cross-reactivity with HIT antibodies)

Reference: PMID: 30482774 (ASH HIT Guidelines 2018)

---

ICU Scenario 3: Antiplatelet Reversal for Emergency Surgery

Clinical Situation: Patient on dual antiplatelet therapy (aspirin + ticagrelor) presents with acute subdural hematoma requiring craniotomy.

Approach:

1. Stop antiplatelet agents immediately
2. Assess platelet function if available:
   • TEG Platelet Mapping
   • Multiplate (ASPI + ADP tests)
3. Platelet transfusion:
   • 1-2 adult doses (one dose for aspirin effect, additional for P2Y12 inhibition)
   • May need repeat dosing due to circulating drug
4. DDAVP (0.3 mcg/kg IV):
   • Releases vWF from endothelial cells
   • May enhance platelet function
   • Single dose (tachyphylaxis with repeat dosing)
5. Tranexamic acid (TXA):
   • 1g IV bolus then 1g over 8 hours
   • Inhibits fibrinolysis
   • CRASH-3 trial supports early use in TBI (PMID: 31623894)
6. For ticagrelor specifically:
   • Consider idarucizumab if concurrent dabigatran (not applicable here)
   • No specific reversal agent yet
   • Ticagrelor half-life ~7 hours; active metabolite ~9 hours
   • Platelets transfused may also be inhibited by circulating drug

Evidence: PATCH trial showed HARM from platelet transfusion in spontaneous ICH on antiplatelets. However, for SURGICAL bleeding, platelet transfusion remains appropriate. PMID: 27342600

---

7. Progressive Difficulty Questions

Basic Level (Foundation)

Question 1: Q: Define primary hemostasis and state the normal platelet count range.

A: Primary hemostasis is the initial response to vascular injury involving platelet adhesion, activation, and aggregation to form a temporary platelet plug. Normal platelet count: 150-400 x 10^9/L.

---

Question 2: Q: List the contents of platelet alpha granules.

A: Platelet alpha granules contain:

1. Adhesion proteins: vWF, fibrinogen, fibronectin, vitronectin
2. Coagulation factors: Factor V, Factor XI, protein S, PAI-1
3. Growth factors: PDGF, TGF-β, VEGF, EGF
4. Membrane proteins: P-selectin (CD62P), GPIIb/IIIa
5. Chemokines: PF4, RANTES, β-thromboglobulin

---

Question 3: Q: What is the function of GPIb-IX-V complex on the platelet surface?

A: The GPIb-IX-V complex is the primary adhesion receptor on platelets. It binds to von Willebrand factor (vWF) attached to exposed subendothelial collagen, allowing platelet tethering and rolling at sites of vascular injury, particularly under high shear conditions in the arterial circulation.

---

Intermediate Level (Application)

Question 4: Q: Explain the mechanism by which aspirin inhibits platelet function.

A: Aspirin irreversibly inhibits platelet function by:

1. Covalent modification: Aspirin transfers an acetyl group to serine residue 529 in the active site of cyclooxygenase-1 (COX-1)
2. Enzyme inactivation: This prevents arachidonic acid from accessing the catalytic site
3. TXA2 synthesis blocked: Without COX-1 activity, arachidonic acid cannot be converted to prostaglandin H2, the precursor of thromboxane A2
4. Loss of amplification: TXA2 is a potent platelet agonist and vasoconstrictor; its loss reduces platelet activation and recruitment
5. Permanent effect: Platelets are anucleate and cannot synthesize new COX-1, so inhibition lasts the platelet lifespan (8-10 days)

---

Question 5: Q: Compare and contrast the P2Y12 receptor inhibitors clopidogrel and ticagrelor.

A:

---

Question 6: Q: A patient develops a 55% fall in platelet count on day 7 of heparin therapy with a nadir of 65 x 10^9/L. Calculate the 4Ts score and interpret.

A: 4Ts Score Calculation:

• Thrombocytopenia: Fall >50% AND nadir ≥20 = 2 points
• Timing: Day 5-10 of heparin = 2 points
• Thrombosis: If none documented = 0 points
• Other causes: If no other cause apparent = 2 points

Total: 6 points (or 4 if other causes possible)

Interpretation:

• Score of 6-8 = High probability (~40-80% chance of HIT)
• Score of 4-5 = Intermediate probability (~10-30%)

Action: Stop all heparin, start alternative anticoagulant (argatroban), send PF4-heparin antibody test, screen for thrombosis.

---

Exam Level (First Part Standard)

SAQ 1: Platelet Structure and Primary Hemostasis (10 marks)

Time: 12 minutes

Stem: A 45-year-old woman presents with mucocutaneous bleeding. Her platelet count is 180 x 10^9/L but her bleeding time is prolonged.

Question 1.1 (4 marks): Describe the structure of a platelet, including the major surface glycoprotein receptors and their functions.

Question 1.2 (3 marks): Outline the sequence of events in platelet adhesion and aggregation at a site of vascular injury.

Question 1.3 (3 marks): List four conditions associated with normal platelet count but abnormal platelet function.

---

Model Answer:

1.1 (4 marks):

Platelet Structure:

• Anucleate cell fragments derived from megakaryocytes (0.5 mark)
• Diameter: 2-4 μm, lifespan 8-10 days (0.5 mark)
• Open canalicular system (OCS): Membrane invaginations for granule release (0.5 mark)
• Dense tubular system (DTS): Calcium storage, SER remnant (0.5 mark)

Surface Glycoproteins:

---

1.2 (3 marks):

Adhesion (1 mark):

• Vascular injury exposes subendothelial collagen
• vWF binds collagen and uncoils under shear stress
• GPIb-IX-V binds vWF A1 domain → platelet tethering
• GPVI and GPIa/IIa bind collagen directly → stable adhesion

Activation (1 mark):

• GPVI signaling → PLCγ2 → calcium release
• Shape change: disc → sphere with pseudopodia
• Granule release: ADP, serotonin (dense); vWF, fibrinogen (alpha)
• TXA2 synthesis amplifies activation
• Phosphatidylserine exposure for coagulation

Aggregation (1 mark):

• Inside-out signaling → GPIIb/IIIa conformational change
• High-affinity fibrinogen binding
• Fibrinogen cross-links adjacent platelets
• Platelet-platelet bridging forms hemostatic plug

---

1.3 (3 marks):

Conditions with normal count but abnormal function (0.75 marks each):

1. Drug-induced: Aspirin, clopidogrel, NSAIDs
2. Uremia: Accumulated uremic toxins impair function
3. Inherited disorders: Glanzmann thrombasthenia (GPIIb/IIIa deficiency), storage pool disease
4. Acquired conditions: Myeloproliferative disorders, cardiopulmonary bypass, ECMO
5. von Willebrand disease: vWF deficiency affects GPIb-mediated adhesion

---

SAQ 2: Antiplatelet Pharmacology and HIT (10 marks)

Time: 12 minutes

Stem: A 68-year-old man with recent coronary stent placement on dual antiplatelet therapy (aspirin + clopidogrel) is admitted to ICU following emergency laparotomy for perforated diverticulitis. He received prophylactic heparin post-operatively.

Question 2.1 (4 marks): Outline the mechanisms of action of aspirin and clopidogrel.

Question 2.2 (3 marks): On post-operative day 6, his platelet count falls from 220 to 85 x 10^9/L. Describe the pathophysiology of heparin-induced thrombocytopenia (HIT) Type II.

Question 2.3 (3 marks): Describe the principles of HIT management in this patient.

---

Model Answer:

2.1 (4 marks):

Aspirin (2 marks):

• Irreversibly acetylates serine 529 of cyclooxygenase-1 (COX-1) (0.5 mark)
• Prevents conversion of arachidonic acid to prostaglandin H2 (0.5 mark)
• Blocks thromboxane A2 (TXA2) synthesis (0.5 mark)
• Effect lasts platelet lifespan (8-10 days) due to anucleate state (0.5 mark)

Clopidogrel (2 marks):

• Thienopyridine prodrug requiring hepatic activation via CYP2C19 (0.5 mark)
• Active metabolite irreversibly binds P2Y12 receptor (0.5 mark)
• Blocks ADP-mediated platelet activation (0.5 mark)
• Prevents sustained aggregation and amplification of other agonists (0.5 mark)

---

2.2 (3 marks):

HIT Type II Pathophysiology (0.5 marks each):

1. Complex formation: Platelet factor 4 (PF4) released from platelet alpha granules binds heparin
2. Neoepitope: PF4-heparin complex undergoes conformational change exposing neoepitope
3. Antibody production: IgG antibodies form against PF4-heparin complex (typically days 5-10)
4. Immune complex: IgG-PF4-heparin immune complex forms
5. Platelet activation: Immune complex binds FcγRIIa receptors on platelets → intense platelet activation
6. Prothrombotic state: Activated platelets release procoagulant microparticles → massive thrombin generation → paradoxical thrombosis despite thrombocytopenia

---

2.3 (3 marks):

HIT Management Principles (0.5 marks each):

1. Stop ALL heparin: Including flushes, heparin-coated lines, LMWH
2. Alternative anticoagulation: Argatroban (direct thrombin inhibitor) first-line; reduce dose in hepatic impairment (0.5 mcg/kg/min)
3. Do NOT transfuse platelets: May worsen thrombosis ("adding fuel to fire")
4. Laboratory testing: PF4-heparin ELISA for screening; serotonin release assay for confirmation
5. Screen for thrombosis: Duplex ultrasound for DVT; consider CTPA if indicated
6. Warfarin transition: Only after platelet count >150 x 10^9/L (risk of skin necrosis/limb gangrene if started early)

---

8. Viva Practice Questions

Viva Scenario 1: Platelet Physiology

Stem: "Tell me about platelet structure and function in primary hemostasis."

Expected Discussion (10 minutes):

Opening: "Describe the structure of a platelet"

Answer: Platelets are anucleate cell fragments derived from megakaryocyte cytoplasm, measuring 2-4 micrometers in diameter with a lifespan of 8-10 days.

Structurally, platelets contain:

• Plasma membrane with an open canalicular system providing increased surface area for granule release
• Dense tubular system - smooth ER remnant storing calcium for activation
• Cytoskeleton - actin and microtubule rings maintaining discoid shape
• Granules - alpha granules (adhesion proteins, growth factors) and dense granules (ADP, serotonin, calcium)
• Surface glycoproteins - GPIb-IX-V for adhesion, GPIIb/IIIa for aggregation

---

Follow-up 1: "What are the glycoprotein receptors and their functions?"

Answer: The major glycoprotein receptors include:

• GPIb-IX-V complex: Primary adhesion receptor binding vWF on exposed collagen; essential under high shear conditions
• GPIIb/IIIa (integrin αIIbβ3): Final common pathway for aggregation; binds fibrinogen to cross-link platelets; ~80,000 copies per platelet
• GPVI: Primary collagen signaling receptor triggering activation via Src kinases
• GPIa/IIa (α2β1): Secondary collagen receptor for stable adhesion
• PAR-1 and PAR-4: Thrombin receptors; PAR-1 is high affinity, PAR-4 is lower affinity
• P2Y1 and P2Y12: ADP receptors; P2Y12 is target of clopidogrel

---

Follow-up 2: "Walk me through the sequence of platelet plug formation"

Answer: Platelet plug formation occurs in three overlapping phases:

Phase 1 - Adhesion:

• Vascular injury exposes subendothelial collagen
• von Willebrand factor binds collagen via A3 domain
• Under high shear, vWF uncoils exposing A1 domain
• Platelet GPIb-IX-V binds vWF A1, allowing tethering and rolling
• GPVI and GPIa/IIa then bind collagen for stable adhesion

Phase 2 - Activation:

• GPVI signaling activates PLCγ2, releasing calcium from DTS
• Shape change: disc to sphere with pseudopodia
• Granule secretion via SNARE-mediated fusion
• TXA2 synthesis amplifies activation
• Phosphatidylserine flips to outer membrane for coagulation factor assembly

Phase 3 - Aggregation:

• Inside-out signaling activates GPIIb/IIIa
• Conformational change creates high-affinity fibrinogen binding
• Fibrinogen bridges adjacent platelets
• Outside-in signaling leads to clot retraction

---

Follow-up 3: "What is the clinical significance of GPIb versus GPIIb/IIIa deficiency?"

Answer: Both cause bleeding disorders but affect different steps:

GPIb-IX-V deficiency (Bernard-Soulier Syndrome):

• Autosomal recessive
• Impaired adhesion to vWF
• Giant platelets (due to cytoskeletal abnormalities)
• Moderate to severe mucocutaneous bleeding
• Normal aggregation to most agonists except ristocetin

GPIIb/IIIa deficiency (Glanzmann Thrombasthenia):

• Autosomal recessive
• Impaired aggregation (final common pathway blocked)
• Normal platelet count and morphology
• Severe mucocutaneous bleeding
• No aggregation to any agonist except ristocetin

The key distinction: adhesion is preserved in Glanzmann's but aggregation fails; adhesion fails in Bernard-Soulier but aggregation is intact once platelets are activated.

---

Follow-up 4: "How do these receptors integrate with the coagulation cascade?"

Answer: Platelets integrate with coagulation through the cell-based model:

Amplification Phase:

• Small amounts of thrombin generated on TF-bearing cells activate platelets via PAR-1/PAR-4
• Thrombin also activates Factors V, VIII, and XI on platelet surface

Propagation Phase:

• Activated platelets expose phosphatidylserine on outer membrane
• This negatively charged surface allows assembly of tenase (IXa-VIIIa) and prothrombinase (Xa-Va) complexes
• Factor XIa on platelet surface back-activates Factor IX
• Massive thrombin burst occurs on platelet surface
• Alpha granules release Factor V, supplementing plasma-derived Factor Va

Clot Stabilization:

• Thrombin-activated Factor XIII cross-links fibrin
• Platelet actomyosin contraction causes clot retraction
• This closes wound margins and concentrates clot

---

Viva Scenario 2: Antiplatelet Agents and HIT

Stem: "A patient on dual antiplatelet therapy requires emergency surgery. How would you approach this?"

Expected Discussion (10 minutes):

Opening: "What are the commonly used antiplatelet agents and their mechanisms?"

Answer: The main antiplatelet agents include:

COX-1 Inhibitors:

• Aspirin irreversibly acetylates COX-1, blocking TXA2 synthesis
• Effect lasts 8-10 days (platelet lifespan)
• Low dose (75-100 mg) sufficient for antiplatelet effect

P2Y12 Inhibitors:

• Clopidogrel: Thienopyridine prodrug, CYP2C19-dependent, irreversible
• Prasugrel: Thienopyridine, faster activation, more potent, irreversible
• Ticagrelor: Non-thienopyridine, direct-acting, reversible, twice-daily dosing
• Cangrelor: IV agent, rapid onset/offset (1-2 hours)

GPIIb/IIIa Inhibitors:

• Abciximab: Fab antibody, irreversible, 24-48 hour effect
• Eptifibatide: Cyclic peptide, reversible, 4-6 hour effect
• Tirofiban: Non-peptide, reversible, 4-6 hour effect

---

Follow-up 1: "How would you reverse these agents for emergency surgery?"

Answer: Reversal approach depends on the agent:

Aspirin:

• Platelet transfusion (1-2 adult doses)
• DDAVP 0.3 mcg/kg may enhance platelet function
• Transfused platelets may be partially inhibited by circulating aspirin

Clopidogrel/Prasugrel (irreversible P2Y12):

• No specific reversal agent
• Platelet transfusion required
• Wait 5-7 days for meaningful drug washout if possible
• Function testing (Multiplate ADP) can guide adequacy of reversal

Ticagrelor (reversible P2Y12):

• Shorter half-life (7-9 hours for parent compound and metabolite)
• Platelet transfusion may be partially inhibited by circulating drug
• Wait 24-48 hours if possible for drug clearance

GPIIb/IIIa Inhibitors:

• Stop infusion
• Eptifibatide/tirofiban: Reversible, wait 4-6 hours or platelet transfusion
• Abciximab: Irreversible, platelets may be sequestered

---

Follow-up 2: "Post-operatively, the patient is started on heparin prophylaxis. On day 7, platelets drop 60%. What is your differential?"

Answer: The differential for post-operative day 7 thrombocytopenia includes:

Most likely in this context:

• Heparin-induced thrombocytopenia (HIT) - timing (day 5-10), magnitude (>50% fall) highly suggestive
• Sepsis/infection - common cause in post-operative ICU patients
• Drug-induced - antibiotics, sedatives, proton pump inhibitors

Other considerations:

• Dilutional thrombocytopenia from fluid resuscitation
• Ongoing consumption (DIC, hemorrhage)
• Bone marrow suppression
• Mechanical destruction (if on ECMO/VAD)
• Spurious (platelet clumping with EDTA anticoagulant)

With 60% fall on day 7 of heparin, HIT probability is intermediate to high.

---

Follow-up 3: "Describe the pathophysiology of HIT and how you would manage it"

Answer: Pathophysiology: HIT Type II is an immune-mediated prothrombotic disorder:

1. PF4 from activated platelets binds heparin forming PF4-heparin complexes
2. Conformational change exposes neoepitopes
3. IgG antibodies form against PF4-heparin (typically days 5-10)
4. IgG-PF4-heparin immune complexes bind FcγRIIa on platelets
5. Intense platelet activation releases procoagulant microparticles
6. Massive thrombin generation creates prothrombotic state
7. Paradoxically causes thrombosis despite thrombocytopenia

Management:

1. Stop all heparin immediately - including flushes, heparin-coated catheters
2. Calculate 4Ts score - stratify probability
3. Start alternative anticoagulation - argatroban (hepatic metabolism) or bivalirudin
4. Do NOT transfuse platelets - adds activated platelets, worsens thrombosis
5. Laboratory confirmation - PF4-heparin ELISA, SRA if needed
6. Screen for thrombosis - occurs in 30-50% of HIT patients
7. Avoid warfarin until platelets >150 x 10^9/L (risk of skin necrosis)

---

Follow-up 4: "What is the 4Ts score and how do you interpret it?"

Answer: The 4Ts score is a clinical prediction tool for HIT probability:

Components (0-2 points each):

• Thrombocytopenia: >50% fall and nadir ≥20 (2 pts), 30-50% or nadir 10-19 (1 pt), <30% or nadir <10 (0 pts)
• Timing: Day 5-10 or <1 day with recent heparin (2 pts), >day 10 or unclear (1 pt), ≤day 4 without recent heparin (0 pts)
• Thrombosis: New thrombosis, skin necrosis (2 pts), progressive/recurrent (1 pt), none (0 pts)
• oTher causes: None apparent (2 pts), possible (1 pt), definite (0 pts)

Interpretation:

• 0-3: Low probability (<5%) - HIT unlikely, can continue heparin
• 4-5: Intermediate probability (~10-30%) - stop heparin, start alternative, test
• 6-8: High probability (~40-80%) - stop heparin, start alternative immediately

The 4Ts has high negative predictive value - a low score effectively rules out HIT.

---